标题
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 19, Issue 11, Pages 971-991
出版商
Informa UK Limited
发表日期
2019-10-31
DOI
10.1080/14737140.2019.1686979
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
- (2019) Bertha A. Brodin et al. BRITISH JOURNAL OF CANCER
- Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas
- (2019) MYRELLA VLENTERIE et al. ANTICANCER RESEARCH
- Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumors
- (2019) Danielle Braggio et al. CANCER
- Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma
- (2019) L. Tang et al. Clinical & Translational Oncology
- Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
- (2019) Sven Wind et al. CLINICAL PHARMACOKINETICS
- Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma
- (2019) Florence E Chamberlain et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
- (2019) Breelyn A Wilky et al. LANCET ONCOLOGY
- A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor
- (2019) John Glod et al. CLINICAL CANCER RESEARCH
- Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
- (2019) William A. Flavahan et al. NATURE
- Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species
- (2018) Chen-chun Zhong et al. ACTA PHARMACOLOGICA SINICA
- Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
- (2018) Chengying Xie et al. CANCER SCIENCE
- Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways
- (2018) Laura Rosenberg et al. CARCINOGENESIS
- Contemporary Sarcoma Diagnosis, Genetics, and Genomics
- (2018) Inga-Marie Schaefer et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
- (2018) Patrick Schöffski et al. Lancet Respiratory Medicine
- Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-Tissue Sarcoma: Potential Therapeutic implication for Synovial Sarcoma
- (2018) Parag P Patwardhan et al. MOLECULAR CANCER THERAPEUTICS
- Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study
- (2018) S. Stacchiotti et al. EUROPEAN JOURNAL OF CANCER
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Sorafenib for Advanced and Refractory Desmoid Tumors
- (2018) Mrinal M. Gounder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)
- (2017) Bernd Kasper et al. EUROPEAN JOURNAL OF CANCER
- New targets and therapies for gastrointestinal stromal tumors
- (2017) Agnieszka Wozniak et al. Expert Review of Anticancer Therapy
- Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
- (2017) Frank Hilberg et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Long-term Results of Therapy with Sunitinib in Metastatic Alveolar Soft Part Sarcoma
- (2017) Paulina Jagodzińska-Mucha et al. TUMORI
- Long-term Results of Therapy with Sunitinib in Metastatic Alveolar Soft Part Sarcoma
- (2017) Paulina Jagodzińska-Mucha et al. TUMORI JOURNAL
- Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma
- (2017) Kenta Mukaihara et al. PLoS One
- Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines
- (2017) Rieko Oyama et al. Scientific Reports
- Phosphoproteomics in translational research: a sarcoma perspective
- (2016) J. Noujaim et al. ANNALS OF ONCOLOGY
- Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
- (2016) Scott M. Schuetze et al. CANCER
- Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
- (2016) Emiliano Calvo et al. CANCER TREATMENT REVIEWS
- Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
- (2016) R. B. Verheijen et al. CLINICAL CANCER RESEARCH
- Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer
- (2016) E. Wang et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
- (2016) Weifeng Tang et al. CLINICAL PHARMACOKINETICS
- Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting
- (2016) Stéphane Bouchet et al. EUROPEAN JOURNAL OF CANCER
- Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
- (2016) Yongkun Sun et al. Journal of Hematology & Oncology
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
- (2016) Jocelyn P. Wong et al. Cell Reports
- Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
- (2016) Dieter Zopf et al. Cancer Medicine
- Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
- (2015) J. Khalifa et al. BMC CANCER
- SRC inhibition represents a potential therapeutic strategy in liposarcoma
- (2015) Elisabeth Sievers et al. INTERNATIONAL JOURNAL OF CANCER
- Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
- (2015) Francesca Megiorni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
- (2015) B. A. Teicher et al. MOLECULAR CANCER THERAPEUTICS
- Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma
- (2015) Sandra P. D'Angelo et al. ONCOLOGY
- Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma
- (2015) Ryu Yanagisawa et al. PEDIATRIC BLOOD & CANCER
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
- (2015) Estelle Daudigeos-Dubus et al. PLoS One
- In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model
- (2015) Libo Zhang et al. NEOPLASIA
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072
- (2014) B. Kasper et al. ANNALS OF ONCOLOGY
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
- (2014) A B Suttle et al. BRITISH JOURNAL OF CANCER
- Modeling Alveolar Soft Part Sarcomagenesis in the Mouse: A Role for Lactate in the Tumor Microenvironment
- (2014) Matthew L. Goodwin et al. CANCER CELL
- Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
- (2014) I. Judson et al. CLINICAL CANCER RESEARCH
- Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour
- (2014) S. Stacchiotti et al. EUROPEAN JOURNAL OF CANCER
- Activity of sunitinib in extraskeletal myxoid chondrosarcoma
- (2014) S. Stacchiotti et al. EUROPEAN JOURNAL OF CANCER
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis
- (2014) Jae-Cheol Jo et al. INVESTIGATIONAL NEW DRUGS
- Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
- (2014) Mark Linch et al. Nature Reviews Clinical Oncology
- PDGFR reverses EphB4 signaling in alveolar rhabdomyosarcoma
- (2014) M. I. Aslam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-0034 * POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER
- (2013) Z. J. Trnkova et al. ANNALS OF ONCOLOGY
- Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivothrough suppression of PDGFR-β
- (2013) Jun Ohishi et al. BMC CANCER
- Population pharmacokinetic analysis of axitinib in healthy volunteers
- (2013) May Garrett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Sorafenib in patients with progressive epithelioid hemangioendothelioma
- (2013) Christine Chevreau et al. CANCER
- SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells
- (2013) S. Michels et al. CANCER RESEARCH
- Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
- (2013) Roberta Schmieder et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)
- (2013) T. Valentin et al. INVESTIGATIONAL NEW DRUGS
- Cediranib for Metastatic Alveolar Soft Part Sarcoma
- (2013) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth
- (2013) C L Yeung et al. ONCOGENE
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial
- (2013) Nicolas Penel et al. Targeted Oncology
- Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
- (2013) Sabrina Kermiche-Rahali et al. World Journal of Surgical Oncology
- Sunitinib malate in solitary fibrous tumor (SFT)
- (2012) S. Stacchiotti et al. ANNALS OF ONCOLOGY
- An adaptive Src–PDGFRA–Raf axis in rhabdomyosarcoma
- (2012) Jinu Abraham et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- (2012) D Strumberg et al. BRITISH JOURNAL OF CANCER
- Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours
- (2012) U. Lassen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
- (2012) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory
- (2012) Stéphane Bouchet et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)
- (2012) I. Ray-Coquard et al. ONCOLOGIST
- Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis
- (2012) P. Boudou-Rouquette et al. ONCOLOGIST
- Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
- (2012) Chandrajit P. Raut et al. PLoS One
- Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
- (2011) S. Stacchiotti et al. ANNALS OF ONCOLOGY
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
- (2011) M. M. Gounder et al. CLINICAL CANCER RESEARCH
- Saturable absorption of sorafenib in patients with solid tumors: a population model
- (2011) Marilyne Hornecker et al. INVESTIGATIONAL NEW DRUGS
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
- (2011) Christopher L. Morton et al. PEDIATRIC BLOOD & CANCER
- Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction
- (2011) Abdo J. Najy et al. PROSTATE
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
- (2010) N. Penel et al. ANNALS OF ONCOLOGY
- Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy
- (2010) Ryan C. Fields et al. ANNALS OF SURGICAL ONCOLOGY
- The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors
- (2010) Björn Koos et al. CANCER
- Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
- (2010) I. J. Davis et al. CANCER RESEARCH
- Cediranib/AZD2171 Inhibits Bone and Brain Metastasis in a Preclinical Model of Advanced Prostate Cancer
- (2010) J. J. Yin et al. CANCER RESEARCH
- Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
- (2010) John Araujo et al. CANCER TREATMENT REVIEWS
- Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
- (2010) R. Chugh et al. CLINICAL CANCER RESEARCH
- The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
- (2010) Jochen Rössler et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors
- (2010) Elizabeth Fox et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
- (2010) Piotr Rutkowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy in clear cell sarcoma
- (2010) Robin L. Jones et al. MEDICAL ONCOLOGY
- An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy
- (2010) Nikolaos Vassos et al. VIRCHOWS ARCHIV
- Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling
- (2010) Wessen Maruwge OncoTargets and Therapy
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
- (2009) S. E. DePrimo et al. CLINICAL CANCER RESEARCH
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Clinical outcomes of extra-thoracic solitary fibrous tumours
- (2009) I.M. Cranshaw et al. EJSO
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
- (2009) Stefan Sleijfer et al. EUROPEAN JOURNAL OF CANCER
- Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma
- (2009) Grégoire Robert et al. EUROPEAN UROLOGY
- Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
- (2009) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
- (2009) Rashmi Chugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
- (2009) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
- (2008) Brian Shuch et al. BJU INTERNATIONAL
- Extraskeletal myxoid chondrosarcoma
- (2008) Alex D. Drilon et al. CANCER
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate
- (2008) John Thomison et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells
- (2008) G. Ambrosini et al. MOLECULAR CANCER THERAPEUTICS
- Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
- (2007) John M. Maris et al. PEDIATRIC BLOOD & CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now